Associate Director, Early Commercial Strategy & Insights

**About Us** We are developing potentially best in class therapies for patients living with severe autoimmune diseases. Our lead antibody, claseprubart (DNTH103), is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein that drives disease pathology – enabling less frequent and more convenient self-administered subcutaneous injections. Our second clinical candidate, DNTH212 is a first and potentially best in class, bifunctional inhibitor that targets clinically validated and complementary disease modifying mechanisms, Type 1 IFN suppression and B cell modulation – enabling potential for improved clinical outcomes and patient friendly convenient, self-administered subcutaneous injections. To learn more, please visit [](https://www.globenewswire.com/Tracker?data=y1soUaAWOC4-O3vL0KEFIbkGGaBa4ya1R4SlNpK1jBtukuhO2ZH9w-TXAPcKsa2p3Jtspn7hSbVkLAjNmHX0dAp2Ud-bmE_ZHtvRe9ofvs8=) and follow us on [LinkedIn](https://www.globenewswire.com/Tracker?data=YUSNRkO_e7h0w6N1NFAIa4FCvDH07gefrmBCePiIEJWTl1jh8BoVZX_1GPeZyTuWeqpV3jwuwugpYs6_nl0tv4tzWTDe5YkvqT4LcDCV7FY_ufIwcELs4fQovZzi4HoREK0rIO8fOOb9bQifv1PRVg==). --- **About the Role** The Associate Director, Early Commercial Strategy and Insights will be responsible for helping to develop and execute the commercial insights strategy for Dianthus’ programs, DNTH212 and clauseprubart, across multiple autoimmune and rare disease indications. This includes generating actionable market insights, competitive intelligence, forecasting, and strategic recommendations to support development and commercialization planning for DNTH212 in SLE, Sjögrens syndrome, and Dermatomyositis, as well as claseprubart in Myasthenia Gravis (MG), Chronic Inflammatory, Demyelinating Polyneuropathy (CIDP), and Mutifocal Motor Neuropathy (MMN). Reporting to the Senior Director, you will be a key member of a growing commercial organization, partnering closely with cross functional teams to shape development strategy, assess market opportunities, and support critical business decisions across both programs. We are building a culture of individuals who hold our core principles at the center of our operations, with the goal to elevate the care of our patients’ lives. We are open to you working remotely. **Key Responsibilities** - Lead competitive intelligence related to the DNTH212 program – providing relevant and timely information to both the DNTH212 project team and to Dianthus leadership. - Develop and execute a plan to develop a solid understanding of the dynamics underlying key potential markets, including pipeline development, current treatment and likely positioning of future treatments. - Lead development of well-built and fact-based forecasting models for each indication. - Work with the commercial and cross-functional project team to build out the commercial narratives around claseprubart and DNTH212– aimed at investors, patients and physicians - Support lifecycle planning, indication prioritization, and portfolio strategy for both DNTH 212 and claseprubart. - Contribute to market insights development for claseprubart and take part in building out the market insights function at Dianthus **Experience** - Bachelor’s degree is required. Advanced degree in life-sciences is strongly preferred. Must have substantial education in a field relevant to medicine - Experience with rheumatology and/or neurology is strongly preferred - Experience and proficiency analyzing and synthesizing data and information from multiple sources to create a clear and concise story is required - Must have strong communication skills and comfort with presentation to executive leadership - Experience conducting market research – including development of surveys, study-guides etc. is required - Proficiency with MS Excel and experience building forecasts is required - Experience with claims data analysis and/or EHR analysis preferred - Experience conducting/moderating KOL interviews strongly preferred